According to the research report titled ‘Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)’, available with MarketStudyReport, global Alzheimer drugs market was worth USD 6537 million in 2021 and is anticipated to garner profitable returns by the year 2027.

Global Alzheimer drugs market is primarily driven by increasing incidence of various illnesses and poor lifestyle choices among the general public, in consort with growing elderly population across the world.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4597183/  

For the uninitiated, health conditions such as obesity, diabetes, heart disease, and high blood pressure when combined with inactive lifestyles, smoking, poor eating habits, are known to enhance the risk of acquiring Alzheimer's disease.

The top pharmaceutical companies are concentrating on the development of medications that prevent the disease and provide long-term cognitive gains, which is expected to fuel the market trends during the forecast duration.

Moreover, expansion of telehealth services and the growing popularity of online pharmacies, especially in remote areas, as well as development of drugs like Solanezumab and Aducanumab are further supporting industry expansion.

Pervasiveness of Alzheimer’s ailment, alongside increasing R&D initiatives by pharmaceutical companies and research institutes for effective Alzheimer's therapy are expected to augment the global Alzheimer drugs market size.

Based on drug class, the industry is divided into combined drugs, memantine, cholinergic, and others. In terms of distribution channel, the market is online pharmacy, hospital pharmacy, and retail pharmacy.

Regionally, the market spans across North America (U.S., Canada), Europe (UK, Italy, Germany, France), LAMEA, and Asia Pacific (India, Japan, China, Australia).

NervGen Pharma Corp., Eisai Co. Ltd., Daiichi Sankyo Company Ltd., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Eli Lilli and Company, Pfizer Inc., Biogen Inc., Novartis AG, F. Hoffmann-La Roche AG, and AbbVie Inc. are the leading players affecting the worldwide Alzheimer drugs market trends. New product releases, R&D spending, and increased manufacturing capacity are just a few of the primary measures these companies use to boost their market position.